Skip to main content

Table 4 Outcome after month 12; Mortality ratio and incidence of acute exacerbation in patients with ≥ 5% and < 5% decline in VC

From: The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

 

5% decline in VC at Month 3

  
 

No

Yes

Total*

P-value

Subjects

194

67

261*

 

Mortality (%)

4 (2.04)

6 (8.96)

10

0.0203

Acute exacerbation (%)

7 (3.61)

6 (8.96)

13

0.1031

  1. * Patients for whom the changes in VC at month 3 couldn't be calculated were deleted from the analysis.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us